Logo image of BIVI

BIOVIE INC (BIVI) Stock Fundamental Analysis

NASDAQ:BIVI - Nasdaq - US09074F4054 - Common Stock - Currency: USD

1.48  -0.15 (-9.2%)

After market: 1.5 +0.02 (+1.35%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BIVI. BIVI was compared to 571 industry peers in the Biotechnology industry. BIVI has a great financial health rating, but its profitability evaluates not so good. BIVI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BIVI had negative earnings in the past year.
BIVI had a negative operating cash flow in the past year.
BIVI had negative earnings in each of the past 5 years.
In the past 5 years BIVI always reported negative operating cash flow.
BIVI Yearly Net Income VS EBIT VS OCF VS FCFBIVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

BIVI's Return On Assets of -99.36% is on the low side compared to the rest of the industry. BIVI is outperformed by 75.31% of its industry peers.
Looking at the Return On Equity, with a value of -106.72%, BIVI is in line with its industry, outperforming 43.87% of the companies in the same industry.
Industry RankSector Rank
ROA -99.36%
ROE -106.72%
ROIC N/A
ROA(3y)-1103.91%
ROA(5y)-1006.53%
ROE(3y)-1559.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BIVI Yearly ROA, ROE, ROICBIVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

BIVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BIVI Yearly Profit, Operating, Gross MarginsBIVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BIVI has been reduced compared to 1 year ago.
The number of shares outstanding for BIVI has been increased compared to 5 years ago.
The debt/assets ratio for BIVI has been reduced compared to a year ago.
BIVI Yearly Shares OutstandingBIVI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIVI Yearly Total Debt VS Total AssetsBIVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -10.65, we must say that BIVI is in the distress zone and has some risk of bankruptcy.
BIVI's Altman-Z score of -10.65 is on the low side compared to the rest of the industry. BIVI is outperformed by 75.13% of its industry peers.
There is no outstanding debt for BIVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.65
ROIC/WACCN/A
WACCN/A
BIVI Yearly LT Debt VS Equity VS FCFBIVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M -40M

2.3 Liquidity

BIVI has a Current Ratio of 16.94. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.
BIVI has a better Current ratio (16.94) than 90.76% of its industry peers.
BIVI has a Quick Ratio of 16.94. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.
BIVI has a Quick ratio of 16.94. This is amongst the best in the industry. BIVI outperforms 90.76% of its industry peers.
Industry RankSector Rank
Current Ratio 16.94
Quick Ratio 16.94
BIVI Yearly Current Assets VS Current LiabilitesBIVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BIVI have decreased strongly by -24.94% in the last year.
EPS 1Y (TTM)-24.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BIVI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.85%
EPS Next 2Y30.83%
EPS Next 3Y25.16%
EPS Next 5Y23.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIVI Yearly Revenue VS EstimatesBIVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
BIVI Yearly EPS VS EstimatesBIVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIVI. In the last year negative earnings were reported.
Also next year BIVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BIVI Price Earnings VS Forward Price EarningsBIVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BIVI Per share dataBIVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

BIVI's earnings are expected to grow with 25.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.83%
EPS Next 3Y25.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BIVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOVIE INC

NASDAQ:BIVI (2/21/2025, 8:03:34 PM)

After market: 1.5 +0.02 (+1.35%)

1.48

-0.15 (-9.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2025-02-11/amc
Earnings (Next)05-12 2025-05-12/bmo
Inst Owners6%
Inst Owner Change396%
Ins Owners1.24%
Ins Owner Change0%
Market Cap27.31M
Analysts82.86
Price Target5.1 (244.59%)
Short Float %9.22%
Short Ratio1.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-83.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.14
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-15.6
EYN/A
EPS(NY)-4.5
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0
BVpS1.3
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -99.36%
ROE -106.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1103.91%
ROA(5y)-1006.53%
ROE(3y)-1559.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.94
Quick Ratio 16.94
Altman-Z -10.65
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.09%
EPS Next Y22.85%
EPS Next 2Y30.83%
EPS Next 3Y25.16%
EPS Next 5Y23.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-44.03%
OCF growth 3YN/A
OCF growth 5YN/A